Cantor Fitzgerald set a $10.00 target price on Amarin Corporation PLC (NASDAQ:AMRN) in a research report sent to investors on Monday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

AMRN has been the subject of a number of other research reports. BidaskClub cut Amarin Corporation PLC from a sell rating to a strong sell rating in a report on Thursday, August 24th. Zacks Investment Research cut Amarin Corporation PLC from a buy rating to a hold rating in a report on Monday, August 7th. HC Wainwright restated a buy rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a report on Wednesday, August 9th. ValuEngine upgraded Amarin Corporation PLC from a sell rating to a hold rating in a report on Thursday, August 31st. Finally, Jefferies Group LLC restated a buy rating on shares of Amarin Corporation PLC in a report on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $7.75.

Amarin Corporation PLC (NASDAQ AMRN) traded down $0.02 on Monday, reaching $3.51. 570,500 shares of the company were exchanged, compared to its average volume of 1,759,404. Amarin Corporation PLC has a 12-month low of $2.81 and a 12-month high of $4.47. The company has a debt-to-equity ratio of -1.48, a current ratio of 1.63 and a quick ratio of 1.32.

Amarin Corporation PLC (NASDAQ:AMRN) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. The business had revenue of $47.10 million for the quarter, compared to analyst estimates of $45.85 million. The firm’s revenue for the quarter was up 45.4% compared to the same quarter last year. During the same period last year, the company posted ($0.08) EPS. analysts expect that Amarin Corporation PLC will post -0.22 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Amarin Corporation PLC (AMRN) Given a $10.00 Price Target at Cantor Fitzgerald” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/amarin-corporation-plc-amrn-given-a-10-00-price-target-at-cantor-fitzgerald-2/1703236.html.

In other news, insider Steven B. Ketchum sold 63,479 shares of the stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $3.48, for a total transaction of $220,906.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.72% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. University of Notre Dame DU Lac purchased a new position in shares of Amarin Corporation PLC during the 3rd quarter valued at approximately $2,814,000. TD Asset Management Inc. purchased a new position in shares of Amarin Corporation PLC during the 3rd quarter valued at approximately $285,000. Stevens Capital Management LP purchased a new position in shares of Amarin Corporation PLC during the 3rd quarter valued at approximately $229,000. Dynamic Technology Lab Private Ltd boosted its stake in shares of Amarin Corporation PLC by 94.2% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 87,104 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 42,246 shares during the last quarter. Finally, Westside Investment Management Inc. boosted its stake in shares of Amarin Corporation PLC by 1.1% during the 2nd quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 300 shares during the last quarter. Institutional investors own 37.67% of the company’s stock.

About Amarin Corporation PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.